## Yaguang Xi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8943817/publications.pdf

Version: 2024-02-01

126907 91884 4,950 71 33 69 h-index citations g-index papers 74 74 74 8895 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	MicroRNA-like snoRNA-Derived RNAs (sdRNAs) Promote Castration-Resistant Prostate Cancer. Cells, 2022, 11, 1302.	4.1	8
2	MicroRNAs are involved in the development and progression of gastric cancer. Acta Pharmacologica Sinica, 2021, 42, 1018-1026.	6.1	25
3	Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes and Diseases, 2021, 8, 320-330.	3.4	5
4	Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy. Molecular Cancer Therapeutics, 2021, 20, 1295-1304.	4.1	2
5	Genetic Editing of Long Noncoding RNA Using Technology. Methods in Molecular Biology, 2021, 2372, 169-177.	0.9	0
6	CRISPR/Cas9 System to Knockdown MicroRNA In Vitro and In Vivo. Methods in Molecular Biology, 2021, 2300, 133-139.	0.9	3
7	CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus. Biochemical and Biophysical Research Communications, 2020, 533, 1400-1405.	2.1	7
8	Metformin and cancer immunity. Acta Pharmacologica Sinica, 2020, 41, 1403-1409.	6.1	54
9	Bax is involved in the anticancer activity of Velcade in colorectal cancer. Experimental and Therapeutic Medicine, 2017, 14, 3179-3183.	1.8	5
10	Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion. Npj Breast Cancer, 2017, 3, 25.	5.2	74
11	MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer. Chinese Journal of Natural Medicines, 2016, 14, 881-887.	1.3	16
12	CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Scientific Reports, 2016, 6, 22312.	3.3	174
13	LncDisease: a sequence based bioinformatics tool for predicting lncRNA-disease associations. Nucleic Acids Research, 2016, 44, e90-e90.	14.5	70
14	Methylation of the miR-126 gene associated with glioma progression. Familial Cancer, 2016, 15, 317-324.	1.9	19
15	Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGF $\hat{l}^2$ /miR-21 signaling. Oncotarget, 2016, 7, 7979-7992.	1.8	12
16	Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs. Current Pharmacology Reports, 2015, 1, 154-160.	3.0	4
17	Thiazide-sensitive Na <sup>+</sup> –Cl <sup>−<td>np;gt; 2:0</td><td>18</td></sup>	np;gt; 2:0	18
18	Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway. Acta Pharmacologica Sinica, 2015, 36, 1514-1519.	6.1	28

#	Article	IF	CITATIONS
19	Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and $\hat{l}^2$ -catenin-dependent TCF transcriptional activity. Oncogene, 2015, 34, 1499-1509.	5.9	54
20	Panepoxydone Targets NF-kB and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer. PLoS ONE, 2014, 9, e98370.	2.5	70
21	Entecavir Versus Lamivudine Therapy for Patients With Chronic Hepatitis B-Associated Liver Failure: A Meta-Analysis. Hepatitis Monthly, 2014, 14, e19164.	0.2	8
22	MiR-200, a new star miRNA in human cancer. Cancer Letters, 2014, 344, 166-173.	7.2	303
23	MicroRNAs and anticancer drugs. Acta Biochimica Et Biophysica Sinica, 2014, 46, 233-239.	2.0	17
24	SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. Oncology Reports, 2014, 32, 2533-2540.	2.6	14
25	Role of RUNX3 in Suppressing Metastasis and Angiogenesis of Human Prostate Cancer. PLoS ONE, 2014, 9, e86917.	2.5	35
26	MicroRNA and Cancer Chemoprevention. Cancer Prevention Research, 2013, 6, 401-409.	1.5	34
27	MicroRNAs are involved in the self-renewal and differentiation of cancer stem cells. Acta Pharmacologica Sinica, 2013, 34, 1374-1380.	6.1	22
28	Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/ $\hat{l}^2$ -Catenin Signaling. Molecular Cancer Therapeutics, 2013, 12, 1848-1859.	4.1	113
29	Challenges for MicroRNA Microarray Data Analysis. Microarrays (Basel, Switzerland), 2013, 2, 34-50.	1.4	34
30	Hypoxia-regulated microRNAs in human cancer. Acta Pharmacologica Sinica, 2013, 34, 336-341.	6.1	128
31	MicroRNA: A New Player for Cancer Chemoprevention. Journal of Integrative Oncology, 2013, 02, .	0.3	6
32	MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death and Differentiation, 2012, 19, 378-386.	11.2	117
33	Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene, 2012, 31, 4979-4986.	5.9	68
34	Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Molecular Oncology, 2012, 6, 81-87.	4.6	37
35	Testing for Differentially-Expressed MicroRNAs with Errors-in-Variables Nonparametric Regression. PLoS ONE, 2012, 7, e37537.	2.5	3
36	A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and $\hat{l}^2$ -Catenin Transcriptional Activity. Cancer Prevention Research, 2012, 5, 822-833.	1.5	83

#	Article	IF	CITATIONS
37	MicroRNA, epigenetic machinery and lung cancer. Thoracic Cancer, 2011, 2, 35-44.	1.9	14
38	MicroRNA provides insight into understanding esophageal cancer. Thoracic Cancer, 2011, 2, 134-142.	1.9	9
39	Systematic Evaluation of Three microRNA Profiling Platforms: Microarray, Beads Array, and Quantitative Real-Time PCR Array. PLoS ONE, 2011, 6, e17167.	2.5	95
40	Triphenylmethyl Derivatives Enhances the Anticancer Effect of Immunotoxins. Journal of Immunotherapy, 2011, 34, 438-447.	2.4	13
41	Normalizing bead-based microRNA expression data: a measurement error model-based approach. Bioinformatics, 2011, 27, 1506-1512.	4.1	9
42	Spheroidâ€forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry <i>via</i> hsaâ€miRâ€299–5p regulated <i>de novo</i> expression of osteopontin. Journal of Cellular and Molecular Medicine, 2010, 14, 1693-1706.	3.6	50
43	A personalized microRNA microarray normalization method using a logistic regression model. Bioinformatics, 2010, 26, 228-234.	4.1	37
44	MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression. Journal of Biological Chemistry, 2010, 285, 21496-21507.	3.4	370
45	Translational control analysis by translationally active RNA capture/microarray analysis (TrIP–Chip). Nucleic Acids Research, 2010, 38, e104-e104.	14.5	23
46	MicroRNA in Melanoma. Ochsner Journal, 2010, 10, 83-92.	1.1	40
47	Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, Cisplatin, and Ifosfamide. Clinical Cancer Research, 2009, 15, 7161-7169.	7.0	34
48	Nmi (Nâ€Myc interactor) inhibits Wnt/βâ€catenin signaling and retards tumor growth. International Journal of Cancer, 2009, 125, 556-564.	5.1	68
49	Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clinical and Experimental Metastasis, 2009, 26, 739-749.	3.3	18
50	Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene, 2009, 28, 4065-4074.	5.9	384
51	The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics, 2008, 1, 13.	1.5	425
52	Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Experimental Cell Research, 2008, 314, 2110-2122.	2.6	66
53	Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Research, 2008, 10, R22.	5.0	93
54	<i>miR-192</i> Regulates Dihydrofolate Reductase and Cellular Proliferation through the p53-microRNA Circuit. Clinical Cancer Research, 2008, 14, 8080-8086.	7.0	145

#	Article	IF	CITATIONS
55	The Impact of Genomics in Understanding Human Melanoma Progression and Metastasis. Cancer Control, 2008, 15, 202-215.	1.8	24
56	Reduction of Orc6 Expression Sensitizes Human Colon Cancer Cells to 5-Fluorouracil and Cisplatin. PLoS ONE, 2008, 3, e4054.	2.5	32
57	Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. Cancer Genomics and Proteomics, 2008, 5, 1-35.	2.0	9
58	Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncology Reports, 2008, 19, 257-62.	2.6	34
59	CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics and Proteomics, 2008, 5, 37-42.	2.0	34
60	Cav3.1 ( $\hat{l}\pm 1G$ ) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L833-L844.	2.9	26
61	Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. Rna, 2007, 13, 1668-1674.	3.5	506
62	Investigation of miRNA Biology by Bioinformatic Tools and Impact of miRNAs in Colorectal Cancer—Regulatory Relationship of c-Myc and p53 with miRNAs. Cancer Informatics, 2007, 3, 117693510700300.	1.9	11
63	Investigation of miRNA biology by bioinformatic tools and impact of miRNAs in colorectal cancer-regulatory relationship of c-Myc and p53 with miRNAs. Cancer Informatics, 2007, 3, 245-53.	1.9	17
64	Prognostic Values of microRNAs in Colorectal Cancer. Biomarker Insights, 2006, 1, 117727190600100.	2.5	22
65	Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics, 2006, 7, 68.	2.8	34
66	Differentially Regulated Micro-RNAs and Actively Translated Messenger RNA Transcripts by Tumor Suppressor p53 in Colon Cancer. Clinical Cancer Research, 2006, 12, 2014-2024.	7.0	191
67	Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Molecular Cancer Therapeutics, 2006, 5, 3078-3084.	4.1	35
68	Prognostic Values of microRNAs in Colorectal Cancer. Biomarker Insights, 2006, 2, 113-121.	2.5	223
69	Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics and Proteomics, 2006, 3, 317-324.	2.0	144
70	p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 2004, 25, 2201-2206.	2.8	42
71	Esophageal cancer in Chinese population: no polymorphism in codon 149 of P21Waf1/Cip1 cyclin dependent kinase gene. Oncogene, 2002, 21, 7745-7748.	5.9	3